Related Experiment Videos
Quantitative buffy coat analysis in haematological patients compared to standard laboratory methods
T Lindhardt Pedersen1, E Kjaersgaard, T Plesner
1Department of Medicine and Hematology C, Gentofte Hospital, Hellerup, Denmark.
Scandinavian Journal of Clinical and Laboratory Investigation
|October 1, 1990
Summary
The Quantitative Buffy Coat (QBC) instrument offers rapid hematology results but has limitations. Its accuracy is good, but sensitivity for certain white blood cell types is lower than claimed, and safety concerns exist.
Area of Science:
- Clinical Hematology
- Diagnostic Instrumentation
- Laboratory Medicine
Background:
- The Quantitative Buffy Coat (QBC) system is a rapid, automated method for hematological analysis.
- Standard laboratory methods are well-established but can be time-consuming.
Purpose of the Study:
- To evaluate the performance of the Quantitative Buffy Coat (QBC) instrument.
- To compare QBC results with standard methods in a clinical hematology setting.
Main Methods:
- The QBC instrument was tested using samples from a hematology clinic.
- Results were compared against established standard hematological analysis techniques.
- Key parameters evaluated included hematocrit, platelet count, total white blood cell count, and differential white blood cell counts.
Main Results:
- The QBC instrument demonstrated good accuracy for all tested parameters.
- Precision was good, but sensitivity for granulocytes and mononuclear cells was lower than manufacturer claims.
- A significant percentage of samples (up to 40% for platelets) fell outside reliable limits, and many results were unreadable due to ill-defined boundaries.
- Safety concerns were noted regarding potential blood contamination of the centrifuge.
Conclusions:
- While the QBC instrument provides quick results and good accuracy, its utility is limited by issues with sensitivity at low cell counts and sample readability.
- The instrument's safety profile requires improvement to prevent blood contamination.
- Further validation is needed for specific patient populations and low-level cell estimations.